Chad Carr Pediatric Brain Tumor Center

man working in research lab

The mission of the Chad Carr Pediatric Brain Tumor Center is to improve outcomes in all high risk pediatric brain tumors.  The goal is also to expand the clinical and research capacity of the CC-PBTC, building on its solid foundation to become a center of excellence for pediatric brain cancer research.  We have broad early phase clinical trial projects that encompass all high-risk pediatric brain tumor populations.

Led by the collaborative efforts of C.S. Mott Children’s Hospital, Rogel Cancer Center and more than 1,500 dedicated donors, the Chad Carr Pediatric Brain Tumor Center (CC-PBTC) was established at Michigan Medicine in 2018 to pool the diverse ideas and knowledge that can solve childhood brain cancers. The center brings together unmatched expertise from across the University of Michigan (U-M) Health departments of pediatrics, radiology, neurosurgery, radiation, oncology, genetics, and pathology and U-M schools of engineering and public health — as well as renowned international collaborators.

Explore CC-PBTC

About

Learn more about our center

People

Get to know our team

Research

Explore our Research Areas

Clinical Trials

Explore our Clinical Trials

Patient Care

Explore the patient care and clinical trials within the CC-PBTC

Giving

Supporting Cures Through the U-M Chad Carr Pediatric Brain Tumor Center Fund

Learn more
Dr. Koschmann and young patient

CC-PBTC Impact Report

Paving the Way for Cures

View Impact Report

News

See All News brain image in blue grainy white background with yellow floating circles and
Health Lab

Itaconate identified as a new target for pediatric brain tumors called ependymomas

University of Michigan researchers have found that a specific molecule called itaconate drives the development of ependymomas, a pediatric brain tumor. Their findings can help future drug development for children with this type of malignant brain tumor.
Department News

Brain cancer digital twin predicts treatment outcomes

A new machine-learning-based approach to mapping real-time tumor metabolism in brain cancer patients, developed at the University of Michigan, could help doctors discover which treatment strategies are most likely to be effective against individual cases of glioma.
Department News

Defying the Odds Through a Clinical Trial

As part of the inaugural American Association for Cancer Research (AACR) Pediatric Cancer Report for 2025, Dr. Carl Koschmann is featured in a new video highlighting the journey of a young patient diagnosed with diffuse midline glioma (DMG).
headshot of John R. Prensner
Department News

Children's Brain Tumor Network Names Dr. John Prensner as New Scientific Co-Chair

The Children's Brain Tumor Network (CBTN) announced the appointment of John Prensner, MD, PhD, as its new Scientific Co-Chair.
brain scan on computer
Health Lab

FDA clears new DMG treatment: What it means for a deadly pediatric brain tumor

Diffuse midline gliomas are aggressive tumors that begin in the brain or spinal cord. It is universally fatal, and patients typically live for nine to 15 months after diagnosis. The FDA has approved ONC201 (dordaviprone) to treat recurrent H3K27M-mutant diffuse glioma. It's the first-ever FDA-approved treatment for this disease.
Sidney Ritchie
Research News

Brain cancer patient finds a way forward

Sidney Ritchie’s life changed with her diagnosis of an aggressive brain cancer. Now, in her new reality, she finds meaning and purpose through connection, volunteering, and “showing up fully”

To refer a patient for a clinical trial or to learn more about research, contact [email protected].